JP7313696B2 - 増強されたＲＮＡインタラクトーム捕捉（ｅＲＩＣ） - Google Patents
増強されたＲＮＡインタラクトーム捕捉（ｅＲＩＣ） Download PDFInfo
- Publication number
- JP7313696B2 JP7313696B2 JP2020509047A JP2020509047A JP7313696B2 JP 7313696 B2 JP7313696 B2 JP 7313696B2 JP 2020509047 A JP2020509047 A JP 2020509047A JP 2020509047 A JP2020509047 A JP 2020509047A JP 7313696 B2 JP7313696 B2 JP 7313696B2
- Authority
- JP
- Japan
- Prior art keywords
- rna
- eric
- proteins
- rbps
- capture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 132
- 102000044126 RNA-Binding Proteins Human genes 0.000 claims description 105
- 238000000034 method Methods 0.000 claims description 79
- 238000010828 elution Methods 0.000 claims description 65
- 101710159080 Aconitate hydratase A Proteins 0.000 claims description 36
- 101710159078 Aconitate hydratase B Proteins 0.000 claims description 36
- 101710105008 RNA-binding protein Proteins 0.000 claims description 36
- 108091034117 Oligonucleotide Proteins 0.000 claims description 31
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 230000004570 RNA-binding Effects 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 239000000872 buffer Substances 0.000 claims description 20
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 11
- 230000000295 complement effect Effects 0.000 claims description 10
- 238000004132 cross linking Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 9
- 230000029087 digestion Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000010833 quantitative mass spectrometry Methods 0.000 claims description 6
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims description 5
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims description 5
- 108010046983 Ribonuclease T1 Proteins 0.000 claims description 5
- 108091028664 Ribonucleotide Proteins 0.000 claims description 5
- 239000002336 ribonucleotide Substances 0.000 claims description 5
- 238000010008 shearing Methods 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 claims description 3
- 101710146873 Receptor-binding protein Proteins 0.000 claims 5
- 101710137011 Retinol-binding protein 4 Proteins 0.000 claims 5
- 101710183439 Riboflavin-binding protein Proteins 0.000 claims 5
- 102100024544 SURP and G-patch domain-containing protein 1 Human genes 0.000 claims 5
- 239000012620 biological material Substances 0.000 claims 3
- 239000006249 magnetic particle Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 115
- 102000004169 proteins and genes Human genes 0.000 description 110
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 69
- 239000000523 sample Substances 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 54
- 239000011324 bead Substances 0.000 description 47
- 108020004414 DNA Proteins 0.000 description 43
- 108091034057 RNA (poly(A)) Proteins 0.000 description 37
- BNJOZDZCRHCODO-UHFFFAOYSA-N dimethyloxalylglycine Chemical compound COC(=O)CNC(=O)C(=O)OC BNJOZDZCRHCODO-UHFFFAOYSA-N 0.000 description 35
- 108020004999 messenger RNA Proteins 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 26
- 238000011109 contamination Methods 0.000 description 23
- 108010083644 Ribonucleases Proteins 0.000 description 21
- 102000006382 Ribonucleases Human genes 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 230000003993 interaction Effects 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 15
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 108010026552 Proteome Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 102000004389 Ribonucleoproteins Human genes 0.000 description 10
- 108010081734 Ribonucleoproteins Proteins 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000000356 contaminant Substances 0.000 description 9
- 239000012139 lysis buffer Substances 0.000 description 9
- 230000005291 magnetic effect Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 102100034235 ELAV-like protein 1 Human genes 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 101000925870 Homo sapiens ELAV-like protein 1 Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000031018 biological processes and functions Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108020004463 18S ribosomal RNA Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 5
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 102100033714 40S ribosomal protein S6 Human genes 0.000 description 4
- 102100031634 Cold shock domain-containing protein E1 Human genes 0.000 description 4
- 101000656896 Homo sapiens 40S ribosomal protein S6 Proteins 0.000 description 4
- 101000964787 Homo sapiens Zinc finger protein 80 Proteins 0.000 description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- 102100040642 Zinc finger protein 80 Human genes 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010835 comparative analysis Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000028706 ribosome biogenesis Effects 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 101000858267 Homo sapiens Cytochrome b Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 102100026090 Polyadenylate-binding protein 1 Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000001324 spliceosome Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 101100314477 Arabidopsis thaliana TRB2 gene Proteins 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010014380 Autophagy-Related Protein-1 Homolog Proteins 0.000 description 2
- 102000016956 Autophagy-Related Protein-1 Homolog Human genes 0.000 description 2
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 2
- 101710124441 Cold shock domain-containing protein E1 Proteins 0.000 description 2
- 102100025287 Cytochrome b Human genes 0.000 description 2
- 108700015856 ELAV-Like Protein 1 Proteins 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010012887 Poly(A)-Binding Protein I Proteins 0.000 description 2
- 108091036407 Polyadenylation Proteins 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 description 2
- 239000007801 affinity label Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 230000014784 mRNA export from nucleus Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- -1 probes and targets Chemical class 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000008960 regulation of mRNA stability Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000028710 ribosome assembly Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 101150023245 tbp3 gene Proteins 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 108010016119 Alpha-Ketoglutarate-Dependent Dioxygenase FTO Proteins 0.000 description 1
- 102100030461 Alpha-ketoglutarate-dependent dioxygenase FTO Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100029949 Caprin-1 Human genes 0.000 description 1
- 102100026529 Cleavage and polyadenylation specificity factor subunit 6 Human genes 0.000 description 1
- 102100039950 Eukaryotic initiation factor 4A-I Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 101000793727 Homo sapiens Caprin-1 Proteins 0.000 description 1
- 101000855366 Homo sapiens Cleavage and polyadenylation specificity factor subunit 6 Proteins 0.000 description 1
- 101000959666 Homo sapiens Eukaryotic initiation factor 4A-I Proteins 0.000 description 1
- 101001087352 Homo sapiens Poly(U)-binding-splicing factor PUF60 Proteins 0.000 description 1
- 101000893674 Homo sapiens Ras GTPase-activating protein-binding protein 2 Proteins 0.000 description 1
- 101000700735 Homo sapiens Serine/arginine-rich splicing factor 7 Proteins 0.000 description 1
- 101000805481 Homo sapiens Vigilin Proteins 0.000 description 1
- 101000744718 Homo sapiens YTH domain-containing family protein 3 Proteins 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 101100194706 Mus musculus Arhgap32 gene Proteins 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- 102100028102 Non-POU domain-containing octamer-binding protein Human genes 0.000 description 1
- 101710097259 Non-POU domain-containing octamer-binding protein Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100033008 Poly(U)-binding-splicing factor PUF60 Human genes 0.000 description 1
- 101710103012 Polyadenylate-binding protein, cytoplasmic and nuclear Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 229940116863 RNA binder Drugs 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100040857 Ras GTPase-activating protein-binding protein 2 Human genes 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100029287 Serine/arginine-rich splicing factor 7 Human genes 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100037814 Vigilin Human genes 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 101100194707 Xenopus laevis arhgap32 gene Proteins 0.000 description 1
- 102100039674 YTH domain-containing family protein 3 Human genes 0.000 description 1
- 101150035570 ZNF80 gene Proteins 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000014789 establishment of RNA localization Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000020451 formation of translation preinitiation complex Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 102000033952 mRNA binding proteins Human genes 0.000 description 1
- 108091000373 mRNA binding proteins Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000024623 negative regulation of translation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000031479 positive regulation of translation Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 102000028701 rRNA binding proteins Human genes 0.000 description 1
- 108091009356 rRNA binding proteins Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000004725 rapid separation liquid chromatography Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 230000021411 regulation of translational initiation Effects 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000001812 small ribosome subunit Anatomy 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17186948.0 | 2017-08-18 | ||
| EP17186948 | 2017-08-18 | ||
| PCT/EP2018/072348 WO2019034783A1 (en) | 2017-08-18 | 2018-08-17 | IMPROVED RNA INTERACTOME CAPTURE (ERIC) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536491A JP2020536491A (ja) | 2020-12-17 |
| JP2020536491A5 JP2020536491A5 (enExample) | 2021-09-09 |
| JP7313696B2 true JP7313696B2 (ja) | 2023-07-25 |
Family
ID=59702542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020509047A Active JP7313696B2 (ja) | 2017-08-18 | 2018-08-17 | 増強されたＲＮＡインタラクトーム捕捉（ｅＲＩＣ） |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12117437B2 (enExample) |
| EP (1) | EP3669193B1 (enExample) |
| JP (1) | JP7313696B2 (enExample) |
| CN (1) | CN110998332B (enExample) |
| AU (1) | AU2018316551B2 (enExample) |
| CA (1) | CA3073297A1 (enExample) |
| DK (1) | DK3669193T3 (enExample) |
| ES (1) | ES2921301T3 (enExample) |
| HR (1) | HRP20220722T1 (enExample) |
| HU (1) | HUE059038T2 (enExample) |
| PL (1) | PL3669193T3 (enExample) |
| PT (1) | PT3669193T (enExample) |
| RS (1) | RS63423B1 (enExample) |
| WO (1) | WO2019034783A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110205365B (zh) * | 2019-07-02 | 2023-07-25 | 中山大学孙逸仙纪念医院 | 一种高效研究rna相互作用组的高通量测序方法及其应用 |
| GB202101188D0 (en) * | 2021-01-28 | 2021-03-17 | Cambridge Entpr Ltd | Method |
| WO2024097262A1 (en) * | 2022-10-31 | 2024-05-10 | University Of Virginia Patent Foundation | Chemoproteomic capture of rna binding activity in living cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999014226A2 (en) * | 1997-09-12 | 1999-03-25 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues |
| EP1706489B9 (en) * | 2003-12-23 | 2011-01-05 | Santaris Pharma A/S | Oligomeric compounds for the modulation of bcl-2 |
| DK2191016T3 (en) | 2007-08-20 | 2015-06-08 | Gen Hospital Corp | INSULATION OF PROTEIN FACTORS BINDING DIRECT OR INDIRECT WITH NUCLEIC ACIDS |
| US8748354B2 (en) | 2011-08-09 | 2014-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | RNA interactome analysis |
| EP4502607A3 (en) | 2014-02-07 | 2025-05-07 | European Molecular Biology Laboratory | Proteomic sample preparation using paramagnetic beads |
| US20150376612A1 (en) | 2014-06-10 | 2015-12-31 | The General Hospital Corporation | CCCTC-Binding Factor (CTCF) RNA Interactome |
| EP3271460A4 (en) | 2015-03-17 | 2019-03-13 | The General Hospital Corporation | RNA INTERACTOM OF POLYCOMB REPRESSIVE COMPLEX 1 (PRC1) |
-
2018
- 2018-08-17 CA CA3073297A patent/CA3073297A1/en active Pending
- 2018-08-17 US US16/639,795 patent/US12117437B2/en active Active
- 2018-08-17 CN CN201880053251.2A patent/CN110998332B/zh active Active
- 2018-08-17 HR HRP20220722TT patent/HRP20220722T1/hr unknown
- 2018-08-17 JP JP2020509047A patent/JP7313696B2/ja active Active
- 2018-08-17 EP EP18756423.2A patent/EP3669193B1/en active Active
- 2018-08-17 PT PT187564232T patent/PT3669193T/pt unknown
- 2018-08-17 AU AU2018316551A patent/AU2018316551B2/en active Active
- 2018-08-17 WO PCT/EP2018/072348 patent/WO2019034783A1/en not_active Ceased
- 2018-08-17 RS RS20220632A patent/RS63423B1/sr unknown
- 2018-08-17 ES ES18756423T patent/ES2921301T3/es active Active
- 2018-08-17 PL PL18756423.2T patent/PL3669193T3/pl unknown
- 2018-08-17 HU HUE18756423A patent/HUE059038T2/hu unknown
- 2018-08-17 DK DK18756423.2T patent/DK3669193T3/da active
Non-Patent Citations (5)
| Title |
|---|
| Castello, A. et al.，System-wide identification of RNA-binding proteins by interactome capture，Nature Protocols，2013年，８（３），491-500 |
| Hughes, C. S. et al.，Ultrasensitive proteome analysis using paramagnetic bead technology，Molecular Systems Biology，2014年，１０：７５７ |
| Jacobsen, N. et al.，Direct isolation of poly(A)+ RNA from 4M guanidine thiocyanate-lysed cell extracts using locked nucleic acid-oligo(T) capture，Nucleic Acids Research，2004年，３２（７），e64 |
| Michlewski, G. and Caceres, J. F.，RNase-assisted RNA chromatography，RNA，2010年，１６，1673-1678 |
| Rogell, B. et al.，Specific RNP capture with antisense LNA/DNA mixmers，RNA，2017年05月05日，23，1290-1302 |
Also Published As
| Publication number | Publication date |
|---|---|
| HUE059038T2 (hu) | 2022-10-28 |
| EP3669193B1 (en) | 2022-04-06 |
| PT3669193T (pt) | 2022-07-06 |
| RS63423B1 (sr) | 2022-08-31 |
| US20200209228A1 (en) | 2020-07-02 |
| CN110998332B (zh) | 2024-04-09 |
| WO2019034783A1 (en) | 2019-02-21 |
| HRP20220722T1 (hr) | 2022-07-22 |
| AU2018316551B2 (en) | 2024-12-05 |
| US12117437B2 (en) | 2024-10-15 |
| JP2020536491A (ja) | 2020-12-17 |
| ES2921301T3 (es) | 2022-08-23 |
| DK3669193T3 (da) | 2022-07-11 |
| PL3669193T3 (pl) | 2022-07-25 |
| CN110998332A (zh) | 2020-04-10 |
| EP3669193A1 (en) | 2020-06-24 |
| CA3073297A1 (en) | 2019-02-21 |
| AU2018316551A1 (en) | 2020-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Benhalevy et al. | Proximity-CLIP provides a snapshot of protein-occupied RNA elements in subcellular compartments | |
| Perez-Perri et al. | Discovery of RNA-binding proteins and characterization of their dynamic responses by enhanced RNA interactome capture | |
| Perez-Perri et al. | Global analysis of RNA-binding protein dynamics by comparative and enhanced RNA interactome capture | |
| Goldfarb et al. | Targeted CRISPR disruption reveals a role for RNase MRP RNA in human preribosomal RNA processing | |
| Imig et al. | miR-CLIP capture of a miRNA targetome uncovers a lincRNA H19–miR-106a interaction | |
| CN110191962A (zh) | 外来体相关核酸的测序和分析 | |
| Nabeel-Shah et al. | C2H2-zinc-finger transcription factors bind RNA and function in diverse post-transcriptional regulatory processes | |
| CN107109698B (zh) | Rna stitch测序：用于直接映射细胞中rna:rna相互作用的测定 | |
| JP7313696B2 (ja) | 増強されたＲＮＡインタラクトーム捕捉（ｅＲＩＣ） | |
| Wang et al. | An overview of methodologies in studying lncRNAs in the high-throughput era: when acronyms ATTACK! | |
| Xue | Architecture of RNA–RNA interactions | |
| Wolin et al. | SPIDR: a highly multiplexed method for mapping RNA-protein interactions uncovers a potential mechanism for selective translational suppression upon cellular stress | |
| Zhao et al. | Advances in the identification of long non-coding RNA binding proteins | |
| Aydin et al. | SHIFTR enables the unbiased identification of proteins bound to specific RNA regions in live cells | |
| Balzarini et al. | A widely applicable and cost-effective method for specific RNA–protein complex isolation | |
| Luyties et al. | Multi-omics and biochemical reconstitution reveal CDK7-dependent mechanisms controlling RNA polymerase II function at gene 5′-and 3′ ends | |
| Choy et al. | Deciphering noncoding RNA and chromatin interactions: multiplex chromatin interaction analysis by paired-end tag sequencing (mChIA-PET) | |
| Lin et al. | In vivo analysis of RNA proximity proteomes using RiboPro | |
| Kilchert | RNA–Protein Interactomics | |
| Xu et al. | Co-transcriptional RNA processing boosts zygotic gene activation | |
| Pan et al. | Updated Pseudo-seq Protocol for Transcriptome-Wide Detection of Pseudouridines | |
| Beckmann et al. | Probing the RNA-binding proteome from yeast to man: major advances and challenges | |
| Honson et al. | RAPMS 2.0 Improves Specificity and Throughput for Proteomic Identification of RNA Binding Proteins | |
| Zagore | The Molecular Function of the RNA Binding Protein DAZL in Male Germ Cell Survival | |
| Qi et al. | Genome-Wide Mapping of RNA-Protein Associations via Sequencing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210728 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210728 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220608 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220614 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230317 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230614 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230705 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7313696 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |